The left ventricular assist device as a patient monitoring system

Francesco Moscato1,2,3, Christoph Gross1,2, Martin Maw1,2,4, Thomas Schöoglhofer1,2,4, Marcus Granegger4, Daniel Zimpfer4, Heinrich Schima1,2,4

1Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria; 2Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria; 3Austrian Cluster for Tissue Regeneration, Vienna, Austria; 4Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria

Correspondence to: Francesco Moscato, PhD. Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Waehringer Guertel 18-20, AKH-4L, 1090 Vienna, Austria. Email: francesco.moscato@meduniwien.ac.at.

Technological progress of left ventricular assist devices (LVADs) towards rotary blood pumps and the optimization of medical management contributed to the significant improvements in patient survival as well as LVAD support duration. Even though LVAD therapy is now well-established for end-stage heart failure patients, the long-term occurrence of adverse events (AE) such as bleeding, infection or stroke, still represent a relevant burden. An early detection of AE, before onset of major symptoms, can lead to further optimization of patient treatment and thus mitigate the burden of AE. Continuous patient monitoring facilitates identification of pathophysiological states and allows anticipation of AE to improve patient management. In this paper, methods, algorithms and possibilities for continuous patient monitoring based on LVAD data are reviewed. While experience with continuous LVAD monitoring is currently limited to a few centers worldwide, the pace of developments in this field is fast and we expect these technologies to have a global impact on the well-being of LVAD patients.

Keywords: Left ventricular assist device (LVAD); patient monitoring; hemodynamics; adverse events (AE)

doi: 10.21037/acs-2020-cfmcs-218

View this article at: http://dx.doi.org/10.21037/acs-2020-cfmcs-218

Introduction

Left ventricular assist devices (LVADs) are the current therapy of choice for end-stage heart failure, as a bridge to heart transplantation or for permanent use (1). A tremendous improvement in patient survival has been achieved since the first introduction of LVADs. One-year survival improved from 52% with first-generation pulsatile devices (2) to 82% with currently used continuous-flow LVADs (1). However, new challenges for this therapy have become evident with longer LVAD support durations. The burden of adverse events (AE), such as gastrointestinal (GI) bleeding, infection, stroke and right heart failure, were highlighted in the 5th Intermacs report in 2013, which showed a freedom from major adverse event or death of just 30% by the first year after implantation (3). More recent data show a freedom from readmission at one year of 21–23% (4).

Thus, further technological advances and improved patient management have become necessary to enhance the quality of life of LVAD patients, or even to extend the treatment to less advanced stages of heart failure. The recent introduction of fully-magnetically levitated technologies has led to a reduced incidence of major AE. Particularly, the unadjusted first-year freedom from cerebrovascular accidents improved from 86% to 93%. The cumulative number of rehospitalizations in the whole patient population is, however, still high, with 218 rehospitalizations per 100 patients by twelve months (1).

A possible way to reduce the burden of AE is to anticipate them by recognizing the initial derangement that leads to major consequences and to act early to change patient treatment.

Patient monitoring devices and software tools have the potential to provide early recognition of AE and thereby lead to an improvement in patient care (5). For
example, wireless pulmonary artery monitoring resulted in a reduction of heart failure hospitalizations and more frequent changes in medications in the active monitoring group compared to the control group (6,7). Multi-sensor data integration and analysis from cardiac resynchronization therapy devices could predict heart failure events up to thirty-four days before patient presentation (8). While the technological possibilities for LVAD patient monitoring have been proposed and discussed since the early days of continuous-flow LVADs (9-12), it is only recently that monitoring has received increasing attention from the clinical community (13,14).

Data for LVAD patient monitoring can be acquired from a variety of sources (Figure 1), including external devices such as point-of-care international normalized ratio (INR) monitors (15,16), or from implantable devices such as cardioverter-defibrillators (ICD)/pacemakers (17), left atrial pressure sensors (18) and pulmonary artery pressure sensors (19). There have also been developments to include sensors directly into the LVAD system. The pump flow rate sensor has been implemented in one of the first continuous-flow LVADs (20) and has been used since then for patient monitoring. More recently sensors to measure ventricular pressure (21) or volume (22), as well as electrocardiography sensing (23), have been embedded in the LVAD inflow cannula and evaluated in various experimental settings. These sensors are not yet part of clinically available devices. Structured telephone interviews also constitute a relatively accessible source of data that can lead to significant improvements in outcome (24). Arterial blood pressure measurement devices (25), acoustic measurements (26,27) and weighing scales can provide sources of relevant information. Finally, mobile phone apps (28) and activity trackers (29,30) provide a potential for patient monitoring, especially as they support the patients self-monitoring. This may improve patient compliance as the technology may be able to support important tasks, such as adjustment of anticoagulation therapy (31). In this work, the current possibilities of LVAD patient monitoring are summarized, with a particular focus on data available from the LVAD itself that permit continuous monitoring of patient hemodynamics in the out-of-hospital setting, without the need for additional sensors.

LVAD data for patient monitoring

The LVAD pumps blood by transferring rotational kinetic energy into hydrodynamic energy of the fluid flow. The driving torque is generated by an electric motor, usually powered by batteries. In order to ensure proper rotational speed control, the motor current, voltage and impeller speed have to be measured and are therefore available for further processing. Whilst these device measurements seem at a first glance to be unrelated to patient hemodynamics,
in reality they provide the basic elements to estimate the flow-rate through the pump (32), which in turns reflects the interaction between the LVAD, the assisted ventricle and the vascular system. Over the course of at least the last fifteen years, methods and algorithms have been developed to estimate relevant hemodynamic variables from the pump-available data (33-40). In Figure 2, a representative LVAD flow waveform is shown, with the physiological variables that can be derived from it.

Data recorder device and clinical study for 24/7 patient monitoring

To access pump data from patients, a continuous data acquisition system (CDAS) was developed that records pump motor current, power and impeller speed from the HeartWare ventricular assist device (HVAD) controller (Medtronic plc, Minneapolis MN, USA) and stores them on an 8 GB micro-SD card (Figure 3A). Up to four weeks of waveform data can be stored with a time-resolution of 0.02 seconds. Connection to the HVAD pump controller is realized using an optical isolator to avoid any direct electrical linking. The small dimensions of the device (100 mm x 55 mm x 30 mm) allow fitting in the peripherals' bag (Figure 3B). The device also includes a tri-axial accelerometer for recording bag movements from which patient's activity (e.g., step count) can be inferred. Periodic download of data on a computer has to be performed for data processing.

LVAD-based monitoring tools were evaluated in a clinical study [ClinicalTrials.gov ID: NCT01981642 (41)]. Patients implanted with an HVAD device (Medtronic plc, Minneapolis MN, USA), who were over the age of eighteen, were enrolled in the clinical study. Patients received the CDAS in the General Hospital Vienna and were asked to keep it connected to the controller until exchange was necessary (i.e., approx. every four weeks). A database was developed with MATLAB (The Mathworks Inc., Natick, MA, USA) for analysis of large patient datasets. In addition to the HVAD data the advanced pump flow waveform features (Figure 2) were calculated and stored in the database, as well as the accelerometer data. In total, forty-two patients [age: 58.5 (33.6–71.0) y; body mass index: 26.9 (21.8–37.0) kg/m²; both expressed as median (5–95 percentile); female gender: 14.3%] received the CDAS for more than one day, and 9,201 recordings (each of up to 24 h) were processed. The median duration of the available data recordings was 19.8 hours, with the 5th to 95th percentile of 7.7 to 23.6 hours. In the following sections, key findings from the study will be presented.
Ventricular suction

Ventricular wall collapse and suction occurs if drainage of blood by the LVAD exceeds venous return or if the pumps inflow cannula placement leads to suction of ventricular structures. Suction may lead to damage of the myocardial wall, may induce ventricular arrhythmias or may cause thromboembolic events, because of the disturbed blood flow pathways that arise during such abnormal pump operation. While this phenomenon has been the focus of attention since the early days of LVAD development (11,34,42), it is only recently that observations of suction occurrence during the daily life of LVAD patients has been made. In Figure 4, a continuous recording of LVAD flow and patient activity over the course of three hours is depicted. During this period of time, the patient went home after a routine ambulatory visit. In the first part of the graph, one can observe a flow waveform without suction and a reduced pump flow pulsatility. Physical activity triggered an increase in both mean-flow and flow pulsatility. When the patient returned to previous levels of mean-flow and pulsatility, a long suction cluster (~1 h duration) occurred.

These and similar observations (e.g., circadian behavior) are only possible with a continuous monitoring of pump data. For these initial observations, a systematic analysis of continuous pump data recordings from a subgroup of ten patients was performed. Patients were followed over a period of fifteen days after the first ambulatory visit post rehab-clinic discharge (43). Five patients showed high-suction (HS) rates with episodes ranging from 5% to 40% suction beats of all beats in one hour, while the other five patients had <5% suction/h throughout the observation period (low-suction, LS). Four out of five HS patients had ischemic heart failure etiology, whereas four out of five LS patients had dilatative etiology. Echocardiographic examinations revealed that the left ventricular end-diastolic diameter was smaller in the HS-patients compared to the LS-patients (53.4±8.7 vs. 71.0±8.5 mm, P=0.018). Despite the small number of patients, this study showed, for the first time, that suction can be a concern even in patients that are supposed to be optimally adjusted and clinically stable. Additionally, the study suggested that left ventricular chamber dimensions and intracardiac LVAD position might contribute to an increased occurrence of suction. Evaluation in a larger patient cohort is necessary to confirm these findings, however, these first observations are already very compelling.

Cardiac rhythms

The heart rate, its variability, and in particular arrhythmias, bear important information about the cardiac and overall patient condition (44). Continuous monitoring of cardiac rhythms can be done if the LVAD patient has also an ICD/pacemaker implanted (45), however, it is the combination of both cardiac rhythms and pump data that can lead to a deeper understanding of the relationship between and arrhythmic events and hemodynamic derangements [e.g., when suction occurs (43,46)]. In Figure 5, two examples of ECG-tracings juxtaposed to pump flow waveform are shown. It is worth noting that ventricular suction is present before, during and after the tachycardia event.

Suction can either induce tachycardia or even occur as a result from tachycardia. To shed some light into these mechanisms the occurrence of tachycardia (defined as at
least 5 consecutive beats with heart rate >100 bpm) before, during and after suction periods of different durations were evaluated in the same patient collective reported in reference (43). In Figure 6, results are shown in form of pie charts; 15.5%±3.8% of suction periods showed an association with cardiac arrhythmia (labels IIO, IOI, OII, IOO, OIO, OOII). As the suction duration increases, tachycardia becomes more important: tachycardia precedes suction (all labels beginning with I) 57% of the time when suction is sustained (>5 min duration). Further analysis is needed to elucidate the causal mechanisms; it seems, however, that it is reasonable to say that whenever sustained arrhythmia is present the presence of suction should be investigated.

**Exercise capacity, daily life activity and adverse events**

Monitoring of LVAD data can improve the understanding of hemodynamic unloading and the interaction between the assisted heart and the LVAD in response to exercise. With current LVADs driven at constant speed, an increase in preload typically results in a modest increase in pump flow during exercise (47,48). The major response to increased perfusion demands is due to an increase in heart rate and ventricular ejection towards the aortic valve, both of which can be quantified during exercise using LVAD-based monitoring (49). Chronotropic incompetence or heart rate recovery immediately after exercise can be also easily monitored. Heart rate recovery, in particular, has been shown to be a predictor of clinical outcome and mortality (50,51).

While exercise capacity of LVAD patients has been extensively investigated (52-54) less is known about daily patient activity and how this could be utilized to better understand the impact of AE on patient well-being or even to anticipate/predict them. In Figure 7, two exemplary cases show the amount of steps/day from patients over the course...
Figure 5 Two snapshots from ventricular tachycardia. The ECG is shown with the tachycardia episode (top), the corresponding LVAD pump flow with a typical suction pattern (middle) and the tachogram calculated from LVAD signals (bottom). Note that time scales of ECG and pump flow are slightly different. LVAD, left ventricular assist device. The yellow circles indicate episodes of ventricular tachycardia (VT).
of about one year after LVAD implantation. The first of the two patients (Figure 7A) had to be rehospitalized four times. It is interesting to note how the activity started declining already 50 days before readmission for a major infection (marker number 3). The second case (Figure 7B) shows, on the other hand, that activity after a transient ischemic attack for this patient never returned to the pre-event level.

The combined analysis of exercise tests responses and daily life activity might help to identify differences in patients, particularly with regard to their cardiac function reserve (55).

**Trend data analysis**

High time-resolution data provide an extremely granular level of detail, with the possibility to observe even single-
beat events. However, these data are not generally available in commercial devices yet. The analysis of so-called log-files, which are pump data sampled at time intervals in the range of minutes to hours, is available in most devices and it has a potential to quickly translate into patient treatment improvements. Trend analyses of the pump signals can indeed indicate both patient recovery but also dysfunction. Increase of circadian variation of LVAD flow has been shown as a sign of post-operative recovery of cardiovascular end-organ function and improved sympathovagal balance (56). On the other hand, the decrease of circadian variations has been associated to thrombotic events, potentially anticipating clinical manifestation by 12±6 days (57). Pump thrombosis can also be observed and managed with the help of log-file analysis of average motor power data (58-60). A steady decrease of pump flow together with a progressive disappearance of circadian rhythm can be also indicative of GI bleeding and resulting hypovolemia, as shown in Figure 8.

The developed methods and algorithms presented so far can be also used in any LVAD for which pump data (motor current and speed at least) can be retrieved, or when a direct measurement of pump flow is available. An initial clinical experience of patient telemonitoring with LVADs with an embedded pump flow sensor (Heart Assist 5 and the aVAD, ReliantHeart Inc., Houston, TX, USA) has been reported in (61). Here, eleven patients were observed using the available telemonitoring tool over an average follow-up time of 221.6±158.1 days. Both flow waveform and trend-data analysis allowed timely recognition of abnormalities such as pump thrombosis and hypovolemia.

**Figure 8** Trend data analysis in a patient that had to be readmitted because of GI bleeding. GI, gastrointestinal; Hb, hemoglobin; INR, international normalized ratio.

Translating pump monitoring to better patient outcomes

The diagnostic possibilities arising from waveform and trend analysis of pump data are clearly not limited to the one presented here, and we anticipate that much more applications will come in the near future. The analysis of pump signals and how these correlate to AE and/or physiologically relevant states is only the first step. The integration of LVAD data with a variety of other available data (Figure 1) appears to be the natural following step. This could also include the fusion with data provided by sensors integrated in future LVADs. Sensors integrated in the LVAD to measure ventricular pressure or volume would be very valuable in assessing the supported heart function, however reliability and/or long-term stability issues might...
limit their utility. Indeed, the more components and features a device has, the more probable it is that their failure occurs. Therefore, only a proper combination of pump-intrinsic signals as motor current/speed and additional integrated sensors for ventricular pressure/volume, will lead to reliable and clinically relevant pump and patient monitoring.

While innovation in pump monitoring provides additional information on patient status, interpretation of this data is the missing link to clinical implementation. Ultimately, intervention based on this data is the goal, not excellent hindsight. For this purpose, the newly gathered information has to be processed and ultimately distilled into actionable items for the clinician or the patient. In a first step, guidelines on interfacing with pump monitoring enables one to navigate the vast sea of information. Should a loss of circadian rhythm indicate a call to the caregiver? Is transient suction acceptable, or already trigger a call to the clinic? When should pump monitoring even be consulted? The pump monitoring tools do not inherently provide answers to these questions, but rather a means of observing previously unseen behavior, especially in the long times between patient visits to the outpatient clinic. Only increased experience with these tools will show their true utility. We believe that in the complex treatment of heart failure with LVADs, these tools of pump monitoring could save precious days or even weeks before intervention and help guide treatment strategy.

**Conclusions**

We live in a society that collects data at an unprecedented rate. In 2017, an estimate of the amount of unstructured data that a human being produces in a life time was 1,100 terabytes (62). This data typically comes from monitoring devices such as activity trackers or smart watches. In the same estimation, structured and labeled data, like these coming from electronic medical records, would account for 0.4 terabytes. We are currently extracting meaningful information for unstructured (e.g., LVAD) data, with use of human structured health records as a reference. It is, however, plausible to think of this process of data extraction, integration and interpretation as a process of teaching machines to support the diagnostic, prognostics and therapeutic skills of a physician, or even to directly feed-back information to a patient providing early warnings about underlying medical conditions (**Figure 9**). This ensures a vigilant system, without additional load on the caregiver. However, it is important that the additional...
information coming to the clinician or patient is signal, rather than noise.

While this scenario might seem still far away, the pace of developments in artificial intelligence has been accelerating in the past few years and we foresee that this will also have a significant impact on LVAD patients.

Acknowledgments

Funding: Parts of this research have been funded by the Austrian Science Fund (FWF-KLI357) and the Ludwig Boltzmann Institute for Cardiovascular Research.

Footnote

Conflicts of Interest: FM: Research Grant (Medtronic); TS: Consultant, Advisor (Abbott, Medtronic); Research Grant (Medtronic); MG: Consultant, Research Grants (BerlinHeart); DZ: Advisor, Proctor, Research Grants, non-financial Support, Speaker Fees (Abbott, Medtronic, Berlin Heart, Edwards); HS: Research Grant, Advisor (Medtronic). The other authors have no conflicts of interest to declare.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References


